PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
We are happy to announce one more award for MultiplexDX! Less than one month after receiving three Central European Startup Awards (CESAwards) during the national round in Slovakia, MultiplexDX won the CEE regional round in the Best Social Impact Startup category. The CESAwards’ regional round was held in Warsaw, Poland, on the 24th of October, 2018. This year, the 5th for the CESAwards, its winners were selected from over 3,500 applicants from 10 CEE countries, and more than 40,000 individual public voters supported the finalists during the selection process. The Best Social Impact Startup category is designated for innovative companies which develop and implement solutions to social, cultural, or environmental issues, and have shown the greatest progress over the last year.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“It was such a pleasant surprise and a big honor for us to be chosen as the ‘Best Social Impact Startup’ from 10 Central and Eastern European countries. We’re actually the first company from Slovakia to win any award in the regional CESAwards round. Now we’ve earned entry to the Global Grand Finale in Guangzhou, China. Let’s keep our fingers crossed, as the best startups from 60 countries worldwide will compete in this final round!”
Dr. Cekan also mentioned that such competitions are always a great chance to see what impression the company makes and how competitive it is in general.
For the CESAwards’ Grand Finale, the company was represented by its Head of Marketing, Marina Marinkevich, who expressed the highest respect to the organizers and participants of the event:
“On behalf of the MultiplexDX team, I'd like to thank the organizers, jury, and public voters for their great trust and inspiration. We will do our best to eliminate cancer misdiagnosis in the world and help thousands of people. Also, we'd like to share this award with all the participants. As it was said today during the Ecosystem Summit, we’re all future-shapers, and all of us are winners because we are developing and pushing incredible ideas to the market together!”
This is precisely the main goal of the CESAwards, which aims to build and develop the startup ecosystem with its unique series of events. This year, 10 countries (Austria, Bulgaria, Czechia, Croatia, Hungary, Poland, Romania, Serbia, Slovakia, Slovenia) were competing in 14 categories, and each country provided a national winner for each category in the Grand Finale. The competition has been running since 2014, with MultiplexDX becoming the first participant from Slovakia to succeed in the regional round.
The Central European Startup Awards is the biggest no-pitch, no-conference startup festival in the Central European region. It is a part of the Global Startup Awards, providing an annual spotlight to those who dare to dream big and shape our future. It brings together the best ideas and minds from 60 countries worldwide to celebrate the entrepreneurial spirit and the unique ecosystems of startups.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.